- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
GPBCH 2018 Annual Report
The Greater Philadelphia Business Coalition on Health (GPBCH) seeks to increase the value of health benefit spending for its employer members by improving workforce and community health, increasing healthcare quality and safety, and reducing health care costs. Here is a summary of GPBCH's activities in 2018.
From Neil Goldfarb, president and chief executive officer of the Greater Philadelphia Business Coalition on Health
I am pleased to share with you this Annual Report for the Greater Philadelphia Business Coalition on Health, summarizing our activities and accomplishments for the 2018 Fiscal Year. As is reflected in the report, the Coalition's portfolio of educational programming and projects in support of our mission of improving population health and the value delivered to employers by the healthcare system continued to expand over the past year. Our key activities have had a measurable impact on patient safety and workforce obesity and diabetes risk, and while other accomplishments are more difficult to quantify, we know we are having an impact.
Looking ahead to 2019, our activities will continue to address the most challenging issues facing employers in our region, such as improving diabetes management, eliminating wasteful services, and identifying best practices for managing specialty pharmaceuticals.
AI in Health Care: Balancing Governance, Innovation, and Trust
September 2nd 2025In this conversation with Reuben Daniel, associate vice president of artificial intelligence at UPMC Health Plan, we dive into how UPMC Health Plan builds trust with providers and members, discuss challenges of scaling AI effectively, and hear about concrete examples of AI's positive impact.
Listen
Impact of Amivantamab-Lazertinib on EGFR, MET Resistance Alterations in NSCLC: Danny Nguyen, MD
September 15th 2025The combination of amivantamab and lazertinib in first-line non–small cell lung cancer (NSCLC) significantly reduces resistance mechanisms with implications for second-line treatment, said Danny Nguyen, MD, of City of Hope.
Read More
